摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine | 202580-70-9

中文名称
——
中文别名
——
英文名称
4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine
英文别名
4-chloro-8-(2,4-dichlorophenyl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazine;4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]-pyrazolotriazin
4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine化学式
CAS
202580-70-9
化学式
C13H9Cl3N4
mdl
——
分子量
327.6
InChiKey
SUIBMWPIPMENNY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.57±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    20
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    43.1
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    N-乙基正丁胺4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine四氢呋喃 为溶剂, 生成 Butyl-[8-(2,4-dichloro-phenyl)-2,7-dimethyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-ethyl-amine
    参考文献:
    名称:
    4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine:  A Potent, Orally Bioavailable CRF1 Receptor Antagonist
    摘要:
    Structure-activity studies; in the pyrazolo[1,5-a]-1,3,5-triazine series led to the discovery that compound 11i (DMP696) is a potent hCRF(1) receptor antagonist (K-i = 1.7 nM vs 7.5 nM for alpha-hel-CRF(9-41), hCRF(1) adenylate cyclase IC50 = 82 nM vs 286 nM for alpha-hel-CRF(9-41)). Compound 11i has excellent oral pharmacokinetic profiles in rats and dogs (37% and 50% oral bioavailabilities, respectively). This compound displays good activity in the rat situational anxiety model (MED = 3 mg/kg (po)), whereas a literature standard 1 (CP154526-1) was inactive (MED > 30 mg/kg (po)). Analogue 11i reduced stereotypical mouth movements in rhesus monkeys by 50% at 21 mg/kg (po) using the human intruder paradigm. Overall, the profile of pyrazolotriazine 11i indicates that hCRF1 receptor antagonists may be anxiolytic agents, which have reduced motor side effect profiles.
    DOI:
    10.1021/jm9904351
  • 作为产物:
    参考文献:
    名称:
    4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine:  A Potent, Orally Bioavailable CRF1 Receptor Antagonist
    摘要:
    Structure-activity studies; in the pyrazolo[1,5-a]-1,3,5-triazine series led to the discovery that compound 11i (DMP696) is a potent hCRF(1) receptor antagonist (K-i = 1.7 nM vs 7.5 nM for alpha-hel-CRF(9-41), hCRF(1) adenylate cyclase IC50 = 82 nM vs 286 nM for alpha-hel-CRF(9-41)). Compound 11i has excellent oral pharmacokinetic profiles in rats and dogs (37% and 50% oral bioavailabilities, respectively). This compound displays good activity in the rat situational anxiety model (MED = 3 mg/kg (po)), whereas a literature standard 1 (CP154526-1) was inactive (MED > 30 mg/kg (po)). Analogue 11i reduced stereotypical mouth movements in rhesus monkeys by 50% at 21 mg/kg (po) using the human intruder paradigm. Overall, the profile of pyrazolotriazine 11i indicates that hCRF1 receptor antagonists may be anxiolytic agents, which have reduced motor side effect profiles.
    DOI:
    10.1021/jm9904351
点击查看最新优质反应信息

文献信息

  • Synthesis of [O-methyl-11C]-4-(1,3-dimethoxy-2-propylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine ([11C]DMP696): a potential PET ligand for CRF1 receptors
    作者:J. S. Dileep Kumar、Vattoly J. Majo、Norman R. Simpson、Jaya Prabhakaran、Ronald L. Van Heertum、J. John Mann
    DOI:10.1002/jlcr.885
    日期:2004.11
    Synthesis of [O-methyl-11C]-4-(1,3-dimethoxy-2-propylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine ([11C]DMP696), a highly selective CRF1 antagonist has been achieved. The total time required for the synthesis of [11C]DMP696 is 30 min from EOB using [11C]methyl triflate in THF, with a 16% yield (EOS) and >99% chemical and radiochemical purities along with a specific activity of >2000 Ci/mmol (EOS). Copyright © 2004 John Wiley & Sons, Ltd.
    高选择性 CRF1 拮抗剂[O-甲基-11C]-4-(1,3-二甲氧基-2-丙基基)-2,7-二甲基-8-(2,4-二氯苯基)[1,5-a]吡唑并-1,3,5-三嗪([11C]DMP696)的合成已经完成。在 THF 中使用 [11C]methyl triflate 从 EOB 合成 [11C]DMP696 总共需要 30 分钟,收率为 16%(EOS),化学纯度和放射化学纯度大于 99%,比活度大于 2000 Ci/mmol(EOS)。Copyright © 2004 John Wiley & Sons, Ltd. All Rights Reserved.
  • Azolo triazines and pyrimidines
    申请人:Bristol-Myers Squibb Pharma Company
    公开号:US06358950B1
    公开(公告)日:2002-03-19
    Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    公告释放因子(CRF)拮抗剂I或II的公式:及其在治疗焦虑,抑郁和其他精神,神经系统疾病以及免疫,心血管或心脏相关疾病的治疗中的使用,以及与心理病理障碍和压力相关的结肠过敏性治疗。
查看更多